多西紫杉醇与多西紫杉醇联合卡铂治疗老年晚期非小细胞肺癌的疗效观察  

Clinical Observation of Single-agent Docetaxel and Docetaxel Combined with Carboplatin in Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

作　　者：刘群[1] 安琨[2] 刘杰[1] 王哲海[1] 

机构地区：[1]山东省肿瘤防治研究院内三科,济南250117 [2]山东省医学科学院研教中心

出　　处：《肿瘤防治研究》2009年第1期68-70,共3页Cancer Research on Prevention and Treatment

摘　　要：目的比较单药多西紫杉醇(Docetaxel,TXT)和TXT联合卡铂(Carboplatin,CBP)即TC方案治疗老年晚期非小细胞肺癌(Non-small cell lung cancer,NSCLC)的疗效及不良反应的差异。方法46例晚期NSCLC老年患者,随机分为两组:TXT组给予TXT50mg/m2,第1天,每2周重复;TC组给予TXT40mg/m2,第1天,CBP300mg/m2,第1天,每2周重复。结果两组有效率(36.4%vs41.7%,P=0.77)和中位生存期(9.2月vs7.9月,P=0.13)差异均无统计学意义。TXT组患者生活质量改善优于TC组(77.3%vs45.8%,P=0.03),且Ⅲ+Ⅳ度白细胞减少发生率明显低于TC组(18.2%vs54.2%,P=0.02)。两组非血液学毒性较温和,耐受性良好。结论与TC方案相比,TXT单药2周方案治疗老年NSCLC疗效相当,耐受性及生活质量更好,值得临床进一步观察研究。Objective To evaluate the effects and adverse reactions of single-agent docetaxel and docetaxel combined with carboplatin in elderly patients with advanced non-small cell lung cancer （NSCLC）. Methods Monotherapy group： docetaxel 50 mg/m2 d1, repeated every 2 weeks. Combination therapy group： docetaxel 40 mg/m2 d1, carboplatin AUC = 5 d1, repeated every 2 weeks. Results There was no statistical difference in effective rate（36. 4% vs 41.7%, P = 0. 77）and median survival time （9. 2 months vs 7. 9 months, P = 0. 13）in two groups. The improvement rate of quality of life with monotherapy group was higher than combination therapy group（77. 3% vs 45.8%, P = 0. 03）. In grade Ⅲ to Ⅳ neutropenia was significantly different in the two groups（18. 2% vs 54. 2%, P = 0. 02）. Other toxicities were mild and generally well tolerated. Conclusion Compared to combination therapy, 2-weekly docetaxel monotherapy showed therapeutic equivalence in elderly patients with advanced NSCLC. The quality of life can be preferably improved and the toxicity is tolerable.

关 键 词：多西紫杉醇 卡铂 老年 非小细胞肺癌 单药化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]